Workflow
Inotiv(NOTV)
icon
Search documents
Inotiv(NOTV) - 2023 Q1 - Quarterly Report
2023-02-14 20:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) IN ...
Inotiv(NOTV) - 2023 Q1 - Earnings Call Transcript
2023-02-14 02:22
Inotiv, Inc. (NASDAQ:NOTV) Q1 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Devin Sullivan - The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets David Windley - Jefferies Tim Daley - Wells Fargo Operator Hello, and welcome to Inotiv Inc.'s First Quarter Fiscal 2023 Financial R ...
Inotiv(NOTV) - 2022 Q4 - Annual Report
2023-01-12 22:42
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) | INDIAN ...
Inotiv(NOTV) - 2022 Q4 - Earnings Call Transcript
2023-01-11 01:02
Inotiv, Inc. (NASDAQ:NOTV) Q4 2022 Earnings Conference Call January 10, 2023 5:00 PM ET Company Participants Devin Sullivan - Investor Relations, The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv, Inc.'s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call ...
Inotiv (NOTV) Investor Presentation - Slideshow
2022-11-23 19:37
WHERE Insights LEAD TO >> answers 》》 Company Presentation November 2022 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation ReformAct of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially fromthose projected. Forward-looking statements can often be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strat ...
Inotiv(NOTV) - 2022 Q3 - Quarterly Report
2022-08-12 21:17
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) INDIAN ...
Inotiv(NOTV) - 2022 Q3 - Earnings Call Transcript
2022-08-11 03:12
Financial Data and Key Metrics Changes - Total revenue for Q3 2022 grew sevenfold to $172.7 million, with adjusted EBITDA increasing to $37 million or 21.4% of total revenues [11][35] - Consolidated net loss totaled $3.8 million or a negative $0.16 per share compared to net income of $2.6 million or $0.18 per share in Q3 2021 [42] - Interest expense increased to $8.4 million from $0.4 million in the prior year due to higher debt balance and interest rates [41] Business Segment Data and Key Metrics Changes - DSA segment revenue reached $49.2 million, a 114.8% increase from $22.9 million in Q3 2021, driven by organic growth and acquisitions [35][11] - RMS segment revenue was $123.4 million, reflecting strong incremental revenue from acquisitions [21][36] - DSA gross profit was $21.8 million or 44.3% of segment revenue, up from $7.6 million or 33.2% in the prior year [37] Market Data and Key Metrics Changes - DSA backlog at the end of Q3 was $143.2 million, up 7% from $133.6 million on March 31, 2022, and up 131% from $62 million on June 30, 2021 [44] - The book-to-bill ratio for the DSA segment was 1.19x for Q3 2022, with net awards remaining the same as the previous quarter [43] Company Strategy and Development Direction - The company is focused on expanding capacity and developing new service lines in response to client demand, with significant investments in recruiting and facilities [9][10] - A site optimization plan is being implemented to enhance services and improve margins in the RMS business [9][22] - The acquisition of Protypia adds capabilities in large molecule bioanalytical services, particularly in immuno-oncology and gene therapy [13][66] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent market concerns but noted continued high demand for services and a strong backlog [28][29] - The company is amending its fiscal year 2022 revenue guidance to at least $550 million, up from $510 million, reflecting positive sales trends [26] - Management remains cautious about the economic environment but is committed to disciplined capital allocation and ongoing investments [32][33] Other Important Information - Capital expenditures for the quarter totaled $16.1 million or 9.3% of revenue, with year-to-date CapEx at $31.3 million or 7.9% of revenue [46] - The company has increased headcount by 13.5% over the last six months to support growth, with plans for an additional 8.5% increase in the next six months [33] Q&A Session Summary Question: Clarification on DSA organic growth rate - Management confirmed the organic growth rate of 91.3% and attributed it to increased capacity, favorable pricing, and acquisitions [50][51] Question: Cancellations related to biotech funding - Management indicated that cancellations were primarily due to molecules not being ready rather than broader funding issues [54][55] Question: Future network optimization - Management stated that no significant further optimization or closures are planned at this time [57] Question: Service gross margin outlook - Management noted that favorable pricing and product mix contributed to the current gross margin, but future quarters may see variability [61][62] Question: Demand and supply in nonhuman primate business - Management reported that demand continues to outstrip supply, with no immediate changes expected [70][71] Question: Interest rate exposure and capital structure - Management discussed the variable rate exposure and options for locking in rates, indicating that refinancing to a fixed rate would be expensive [78][82]
Inotiv (NOTV) Investor Presentation - Slideshow
2022-06-15 16:00
WHERE Linsights LEAD IS 》 answers >> Company Presentation June 2022 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements can often be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strateg ...
Inotiv(NOTV) - 2022 Q2 - Quarterly Report
2022-05-13 23:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) INDIA ...
Inotiv(NOTV) - 2022 Q2 - Earnings Call Transcript
2022-05-13 01:30
Inotiv, Inc. (NASDAQ:NOTV) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Kalle Ahl - The Equity Group Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to Inotiv, Incorporated's Second Quarter Fiscal 2022 Financial Results conference call. At this time, all participants are in a listen-only mode. ...